Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 5/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313082 | 0.75 | CA12 (0.54) | CA12CA1CA7CA14CTSL | |
| SCHEMBL8011499 | 0.73 | CA12 (0.52) | CA12CA1CA7CA14CTSL | |
| SCHEMBL13053328 | 0.70 | KMT2A (0.42) | CA12CA1CA7CA14CTSL | |
| SCHEMBL19599995 | 0.70 | KMT2A (0.47) | CA12CA1CA7CA14CTSL | |
| SCHEMBL1219509 | 0.70 | KMT2A (0.43) | CA12CA1CA7CA14CTSL | |
| SCHEMBL1976602 | 0.70 | PPARA (0.42) | CA12CA1CA7CA14CTSL | |
| SCHEMBL13053335 | 0.70 | PPARA (0.42) | CA12CA1CA7CA14CTSL | |
| SCHEMBL31407962 | 0.70 | CA12 (0.48) | CA12CA1CA7CA14SYK | |
| SCHEMBL1219154 | 0.70 | KMT2A (0.42) | CA12CA1CA7CA14CTSL | |
| SCHEMBL14416216 | 0.69 | KMT2A (0.43) | CA12CA1CA7CA14CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047244-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS I | IDENIX PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009014730-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047244-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS I | SERPINB1, SPINT2, PRSS1 | CA12 3636/4885CA1 3683/4885CA7 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.